NDI-010976, A Potent, Liver-Directed, Oral Inhibitor of Acetyl Coa Carboxylase for Non-Alcoholic Steatohepatitis: A Phase 1 Single Ascending Dose Study in Healthy Volunteers
Westlin, W.F, Harriman, G, Harwood, H.J, Kapeller, R, Lennon, S, Miao, W, Stiede, K, Schmalbach, T
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
NDI-010976, a Potent, Liver-Directed, Oral Inhibitor of Acetyl Coa Carboxylase for Non-Alcoholic Steatohepatitis: Pharmacodynamic Effects on Hepatic De Novo Lipogenesis in Obese but Otherwise Healthy Adult Male Volunteers
Westlin, W.F, Blanchette, H, Harriman, G, Harwood, H.J, Kapeller, R, Lennon, S, Miao, W, Beysen, C, Dalidd, M, Turner, S, Stiede, K, Schmalbach, T
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
451 (PB439): First results of a Phase 1 study evaluating safety, PK, PD and clinical activity of STC-15, aMETTL3 inhibitor, in patients with advanced malignancies
Rodon, J., Moser, J.C., Papadopoulos, K.P., Ofir-Rosenfeld, Y., Weisser, H., Snyder, M., Schmalbach, T., Barker, T., Deshpande, D., Skead, B., Hester, D., Sheth, N., Leon, P. Saldana, Blanco-Cepeda, E., Rausch, O., Holz, J.B.
Published in European journal of cancer (1990) (01.10.2024)
Published in European journal of cancer (1990) (01.10.2024)
Get full text
Journal Article
FRI-355 - NDI-010976, A Potent, Liver-Directed, Oral Inhibitor of Acetyl Coa Carboxylase for Non-Alcoholic Steatohepatitis: A Phase 1 Single Ascending Dose Study in Healthy Volunteers
Westlin, W.F., Harriman, G., Harwood, H.J., Kapeller, R., Lennon, S., Miao, W., Stiede, K., Schmalbach, T.
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
PS108 - NDI-010976, a Potent, Liver-Directed, Oral Inhibitor of Acetyl Coa Carboxylase for Non-Alcoholic Steatohepatitis: Pharmacodynamic Effects on Hepatic De Novo Lipogenesis in Obese but Otherwise Healthy Adult Male Volunteers
Westlin, W.F., Blanchette, H., Harriman, G., Harwood, H.J., Kapeller, R., Lennon, S., Miao, W., Beysen, C., Dalidd, M., Turner, S., Stiede, K., Schmalbach, T.
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer
Stephenson, J., Richards, D. A., Wolpin, B. M., Becerra, C., Hamm, J. T., Messersmith, W. A., Devens, S., Cushing, J., Goddard, J., Schmalbach, T., Fuchs, C. S.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CPG immunomodulator (CPG 7909), a phase I study
Kim, Y., Girardi, M., McAuley, S., Schmalbach, T.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
A TLR9 CpG immunomodulator in combination with chemotherapy as treatment for advanced non-small cell lung cancer (NSCLS), a randomized, controlled phase II study
Leichman, G., Gravenor, D., Albert, G., Schmalbach, T.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
A TLR9 CpG immunomodulator in combination with chemotherapy as treatment for advanced non-small cell lung cancer (NSCLS), a randomized, controlled phase II study
Leichman, G., Gravenor, D., Albert, G., Schmalbach, T.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CPG immunomodulator (CPG 7909), a phase I study
Kim, Y., Girardi, M., McAuley, S., Schmalbach, T.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC)
Thompson, J. A., Kuzel, T., Bukowski, R., Masciari, F., Schmalbach, T.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): A phase I, open label dose-escalation study of safety and tolerability
Weiner, G. J., Link, B. K., Leonard, J., Emmanouilides, C., Albert, G., Schmalbach, T.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC)
Thompson, J. A., Kuzel, T., Bukowski, R., Masciari, F., Schmalbach, T.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): A phase I, open label dose-escalation study of safety and tolerability
Weiner, G. J., Link, B. K., Leonard, J., Emmanouilides, C., Albert, G., Schmalbach, T.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study
Leichman, G., Gravenor, D., Woytowitz, D., Mezger, J., Albert, G., Schmalbach, T., Al-Adhami, M., Manegold, C.
Published in Journal of clinical oncology (01.06.2005)
Published in Journal of clinical oncology (01.06.2005)
Get full text
Journal Article